Wegovy alternatives in 2026: access, insurance, cost, results, and side effects compared

Wegovy isn’t the only weight-loss option anymore, and for a lot of patients in 2026 it isn’t even the cheapest or most accessible one. Insurance coverage has shifted twice this year, a genuinely new oral drug reached the market in April, and self-pay pricing across the whole category has dropped since 2024. If you’re weighing Wegovy against another option, here’s how the real alternatives compare right now.

Key takeaways

• Zepbound (tirzepatide) still tends to produce more weight loss than Wegovy on average, and CVS Caremark is bringing it back as a preferred covered option on October 1, 2026, after excluding it for over a year.
• Foundayo (orforglipron), approved April 1, 2026, is the first once-daily oral GLP-1 pill with no food or water restrictions — a genuinely new category, not just a repackaged injectable.
• The Wegovy pill itself is now a self-pay option starting around $149/month at the lowest dose, cheaper than most people expect for an oral GLP-1.
• Rybelsus is not a Wegovy alternative for weight loss — it’s FDA-approved only for type 2 diabetes, despite sharing the same active ingredient as Wegovy.
• Non-GLP-1 options like Qsymia cost a fraction of injectable or oral GLP-1s but produce meaningfully less average weight loss.
• Insurance coverage now changes drug-by-drug and month-by-month — CVS Caremark alone made two separate coverage changes to Zepbound and Foundayo within the same year.
• Compounded semaglutide is no longer a legitimate low-cost alternative for routine use; the FDA closed that pathway through 2025 and 2026.

GLP-1 and dual-agonist alternatives

Zepbound (tirzepatide)

Zepbound activates two receptors (GLP-1 and GIP) instead of Wegovy’s one, and head-to-head data has consistently shown it produces more average weight loss — around 20% versus roughly 14% for semaglutide over comparable trial periods. It’s a weekly injection, same as Wegovy.

The insurance picture has been unstable. CVS Caremark excluded Zepbound from many commercial formularies for over a year starting mid-2025, pushing many patients toward Wegovy by default. That reverses on October 1, 2026, when Zepbound returns as a preferred, covered option — a real shift for anyone whose plan runs through Caremark.

Foundayo (orforglipron)

Foundayo is the newest option on this list and the one most likely to change how people think about “alternatives to Wegovy.” FDA-approved April 1, 2026, it’s a once-daily oral small-molecule GLP-1 agonist — not a peptide like semaglutide, which is why it can be taken any time of day, with or without food or water. That’s a real practical difference from the Wegovy pill, which still requires specific fasting and water-timing rules.

In its approval trials, Foundayo produced average weight loss of 11.2% at the highest dose (36 mg) over 72 weeks in non-diabetic patients — below Zepbound’s typical result, roughly in line with or slightly under Wegovy’s, but with the convenience of a pill that has none of the administration restrictions oral semaglutide requires. Self-pay pricing through LillyDirect starts around $149/month at the lowest dose.

Saxenda (liraglutide)

Saxenda is an older, daily-injection GLP-1 drug. It generally produces less weight loss than Wegovy, Zepbound, or Foundayo, and the daily injection schedule is a real burden compared to once-weekly or once-daily oral options. It remains relevant mainly for patients who didn’t tolerate a newer option well, or whose insurance specifically covers it when it doesn’t cover the others.

Rybelsus (oral semaglutide) — not a weight-loss alternative

Worth stating clearly: Rybelsus contains the same active ingredient as Wegovy, but it’s FDA-approved only for type 2 diabetes, not weight management. A provider prescribing it off-label for weight loss removes any insurance argument and isn’t using the drug as approved. If you want oral semaglutide specifically for weight loss, the Wegovy pill is the FDA-approved version built for that purpose.

Non-GLP-1 alternatives

For patients who don’t want or can’t access a GLP-1-class drug, two older options remain relevant:

• Qsymia (phentermine/topiramate): a daily combination pill, roughly $100/month cash price — far cheaper than any GLP-1 option. Average weight loss in trials runs lower than GLP-1 drugs, though some patients respond well. Side effects include dry mouth, insomnia, and increased heart rate.
• Xenical (orlistat): blocks dietary fat absorption rather than working through appetite hormones. Modest average weight loss (around 3%), available over the counter in a lower dose as Alli. Side effects — oily stool, fecal urgency — are a common reason patients stop.

Effectiveness comparison

These figures come from separate trials with different populations and durations, so treat them as directional, not a precise head-to-head ranking.

Insurance and access in 2026

Coverage for this entire drug class has moved more in 2026 than in any prior year. Three changes worth knowing about:

1. CVS Caremark excluded Zepbound from many commercial formularies for over a year, pushing patients toward Wegovy — that exclusion ends October 1, 2026, when Zepbound returns as a preferred option.
2. CVS Caremark also blocked new-to-market coverage of Foundayo until June 1, 2026, when plans became able to add it where approved.
3. Coverage still varies enormously by plan. A drug being “on formulary” nationally doesn’t guarantee your specific employer plan covers it — checking your plan’s current prior-authorization requirements directly is still the only reliable way to know.

If your insurance doesn’t cover any GLP-1 option for weight loss, self-pay pricing across the category has become genuinely more competitive than it was even a year ago.

Cost breakdown (self-pay, 2026)

Manufacturer self-pay programs have made the injectable and oral GLP-1 drugs far more affordable than their $1,000+ list prices suggest — but only when purchased directly through the manufacturer’s own pharmacy program, not through a standard retail pharmacy without insurance.

Side effects across alternatives

Gastrointestinal side effects — nausea, diarrhea, vomiting, constipation — are common across every GLP-1 and dual-agonist option, including Foundayo, and tend to be worst during dose escalation. Non-GLP-1 options have different side-effect profiles entirely: Qsymia can cause dry mouth, insomnia, or a faster heart rate; orlistat’s main complaint is GI-related (oily stool, urgency) rather than appetite-related.

Every GLP-1 and dual-agonist drug on this list, including Foundayo, carries the same boxed warning for thyroid C-cell tumor risk based on rodent studies, and the same contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

What about compounded semaglutide?

Not a legitimate low-cost alternative anymore. The FDA ended enforcement discretion that allowed mass compounding once the semaglutide shortage resolved in February 2025, and has continued tightening the rules through 2026. Routine compounded semaglutide sold at telehealth-subscription scale no longer meets FDA requirements — the manufacturer self-pay programs above are the legitimate lower-cost route.

How to choose

The right alternative usually comes down to three questions, in this order:

1. What does your insurance actually cover right now? With CVS Caremark’s coverage changing twice in 2026 alone, this is worth confirming directly rather than assuming last year’s answer still applies.
2. Injection or pill? Zepbound and standard Wegovy require a weekly injection. The Wegovy pill and Foundayo are both oral, but Foundayo has no food or water timing restrictions, which the Wegovy pill does.
3. How much weight loss do you need, versus how much side-effect burden you’re willing to accept? Zepbound’s larger average effect comes with a comparable GI side-effect profile to the others; Qsymia and orlistat trade a smaller effect for a much lower cost and a different (non-GI-dominant, for Qsymia) side-effect pattern.

A provider can walk through your specific health history against these options — our guide on tirzepatide’s insurance coverage covers that process in more detail if Zepbound is on your shortlist.

Conclusion

Wegovy is still a solid, well-studied option, but it’s no longer the obvious default it was a few years ago. Zepbound generally outperforms it and is regaining broader insurance coverage this fall. Foundayo brings a genuinely new oral format to the market with fewer restrictions than the Wegovy pill. And for patients focused purely on cost, Qsymia and orlistat remain far cheaper, if less powerful, options. The right choice depends on your insurance, your tolerance for side effects, and how much weight loss you actually need — not on which drug is most talked about.

If you want help sorting through which option fits your situation, book a free consultation with Heally — a licensed provider can review your history and coverage and recommend a starting point.

FAQ

What is the best alternative to Wegovy in 2026? 

It depends on your priority. Zepbound generally produces more weight loss. Foundayo offers a restriction-free oral option. Qsymia and orlistat are the lowest-cost choices if a GLP-1 drug isn’t accessible or affordable for you.

Is Zepbound better than Wegovy? 

On average, yes — head-to-head data shows tirzepatide (Zepbound) produces more weight loss than semaglutide (Wegovy) at comparable trial durations. Individual response varies, and cost and insurance coverage often matter as much as the effectiveness difference.

What is Foundayo, and how is it different from the Wegovy pill? 

Foundayo (orforglipron) is a new oral GLP-1 drug approved in April 2026. Unlike the Wegovy pill, it can be taken at any time of day without food or water restrictions, which makes it easier to fit into a daily routine.

Can I take Rybelsus instead of Wegovy for weight loss? 

Not as an FDA-approved use. Rybelsus contains the same active ingredient as Wegovy but is approved only for type 2 diabetes. The Wegovy pill is the FDA-approved oral semaglutide option specifically for weight management.

Does insurance cover Zepbound in 2026? 

It depends on your plan. CVS Caremark excluded Zepbound from many formularies through most of 2025 and 2026, but that changes October 1, 2026, when it returns as a preferred, covered option on many plans. Checking your specific plan’s current formulary is still the only reliable way to confirm coverage.

What’s the cheapest legitimate alternative to Wegovy? 

Qsymia, at roughly $100/month cash price, is the cheapest option on this list, followed by generic orlistat or over-the-counter Alli. Both produce less weight loss on average than GLP-1 or dual-agonist drugs.

Is compounded semaglutide a cheaper alternative to Wegovy? 

Not a legitimate routine option anymore. The FDA closed the pathway that allowed mass compounding once the national shortage resolved in 2025, and enforcement has tightened further through 2026.

Do all these alternatives have the same side effects?

GLP-1 and dual-agonist drugs (Wegovy, Zepbound, Foundayo, Saxenda) share a similar gastrointestinal side-effect profile. Non-GLP-1 options like Qsymia and orlistat have different side effects entirely, unrelated to the GI system in Qsymia’s case.

Related reading on Heally:

• Wegovy pill dosage guide
• Semaglutide dosing guidelines
• How to get tirzepatide with insurance
• Mounjaro vs Zepbound: what’s actually different

Sources

1. Pharmacy Times — FDA approves orforglipron, first GLP-1 pill without time, food, or water restrictions
2. Eli Lilly — FDA approves Lilly’s Foundayo (orforglipron)
3. NovoCare — Wegovy cost, coverage, and savings resources
4. CVS Health — CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options
5. Healio — FDA approves Foundayo, an oral GLP-1, for adults with obesity
6. FDA — Drug approvals and databases

Medical disclaimer: This article is for informational purposes and reflects publicly available pricing, coverage, and clinical trial information as of September 2026. Pricing and coverage vary by plan, pharmacy, and location. This content does not replace medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any prescription medication.